Lv1
10 积分 2025-03-07 加入
TAPSE/sPAP Ratio to Improve Risk Assessment in Pulmonary Arterial Hypertension
1个月前
已完结
Hemodynamics and Phosphodiesterase-5 Inhibitor Treatment Associated with Survival in Pulmonary Hypertension in Interstitial Lung Disease: A PVRI GoDeep Meta-Registry Analysis
2个月前
已完结
Identification of novel metabolic signatures potentially involved in the pathogenesis of COPD associated pulmonary hypertension
2个月前
已完结
Distinctive metabolomic fingerprint in scleroderma patients with pulmonary arterial hypertension
3个月前
已完结
Integration of Clinical and Hemodynamic Parameters in the Prediction of Long-term Survival in Patients With Pulmonary Arterial Hypertension
3个月前
已完结
Association of Phosphodiesterase-5 Inhibitor Treatment With Improved Survival in Pulmonary Hypertension Associated With COPD in the Pulmonary Vascular Research Institute GoDeep Meta-Registry
4个月前
已完结
Predictors of outcome in pulmonary hypertension associated with lung disease
4个月前
已关闭
Disproportionate impairment in diffusing capacity predicts pulmonary hypertension with an elevated pulmonary vascular resistance in COPD
5个月前
已完结
A global view of pulmonary hypertension
7个月前
已完结
Phosphodiesterase-5 Inhibitor Treatment is Associated with Improved Survival in Pulmonary Hypertension Associated with COPD in the PVRI GoDeep Meta-Registry
8个月前
已完结
皖公网安备34019202002308
